Purpose The purpose of our research was to identify and evaluate synthetic
phosphorothioate-modified CPG oligodeoxynucleotides (CPG-ODNs) activating innate and …

Background C type CpG oligodeoxynucleotides (CpG-C ODNs), possessing the features of
both A type and B type CpG ODNs, exert a variety of immunostimulatory activities and have …

While CpG oligodeoxynucleotides (ODN) are excellent candidates for cancer
immunotherapeutics, the numbers of usable CpG ODNs are limited in current clinical …

Purpose: In order to improve the immunogenicity of whole tumor cell lysate for tumor
vaccine, we have designed a series of CpG ODNs to study their transport and to evaluate …

Synthetic oligodeoxynucleotides (ODNs) containing unmethylated CpG motifs trigger cells
that express Toll-like receptor 9 (including human plasmacytoid dendritic cells and B cells) …

CpG oligodeoxynucleotides (CpG ODNs), the artificial versions of unmethylated CpG motifs
that were originally discovered in bacterial DNA, are demonstrated not only as potent …

Preclinical and early clinical trials indicate synthetic oligodeoxynucleotides containing
unmethylated CG dinucleotides (CpG ODN) have potent immunostimulatory effects and can …

William Coley was the first physician to employ immunotherapy for patients with cancer [1].
His strategy was based on his clinical observation of cancers regressing after the tumor site …

Abstract Type-A CpG oligodeoxynucleotides (ODNs), which have a natural phosphodiester
backbone, is one of the highest IFN-α inducer from plasmacytoid dendritic cells (pDC) via …

Synthetic oligodeoxynucleotides (ODN) containing unmethylated CpG motifs act as immune
adjuvants, accelerating and boosting antigen-specific immune responses. CpG motifs …